title: BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
authors.affiliation: Arthritis Centre, Northwick Park Hospital, Harrow, Middlesex, AAI 30J, UK. andrew.keat@nwlh.nhs.uk
authors.forename: A
authors.initials: A
authors.lastname: Keat
authors.forename: N
authors.initials: N
authors.lastname: Barkham
authors.forename: A
authors.initials: A
authors.lastname: Bhalla
authors.forename: K
authors.initials: K
authors.lastname: Gaffney
authors.forename: H
authors.initials: H
authors.lastname: Marzo-Ortega
authors.forename: S
authors.initials: S
authors.lastname: Paul
authors.forename: F
authors.initials: F
authors.lastname: Rogers
authors.forename: M
authors.initials: M
authors.lastname: Somerville
authors.forename: R
authors.initials: R
authors.lastname: Sturrock
authors.forename: P
authors.initials: P
authors.lastname: Wordsworth
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017281:Cost of Illness; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012720:Severity of Illness Index; D013167:Spondylitis, Ankylosing / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept